June 6, 2011

INCY submits new Drug Application

Incyte Corp, encouraged by data from ruxolitinib for mylefibrosis, submitted a new drug application NDA to the FDA, requiring priority review.


This puts INCY and Novartis NVS substantially ahead of YMI Biosciences (YMI) if approval goes through in the right time frame.

Join the Discussion